系统性硬化症相关间质性肺病的治疗反应生物标志物
本研究基于硬皮病肺研究II的142例随机参与者中92例有纵向生物标志物和临床结局数据者,评估循环生物标志物变化能否预测系统性硬化症相关间质性肺病的进展性肺纤维化。结果显示,KL-6变化与进展性肺纤维化显著相关,在调整基线因素后仍显著(比值比1.4;P=0.0002)。
要点
- 在92例参与者中,19例(21%)符合进展性肺纤维化标准。
- KL-6升高见于发生进展性肺纤维化者,降低见于未发生者(平均变化±标准差 365.68±434.41 vs -207.45±670.26;P<0.001)。
- 在单用霉酚酸酯组,CRP和CXCL4变化也与进展性肺纤维化显著相关。
核心结论
- 接受霉酚酸酯或环磷酰胺治疗后,循环KL-6水平的变化可预测进展性肺纤维化,即使在调整与进展性肺纤维化相关的基线因素后仍显著。
- 作者认为,对系统性硬化症相关间质性肺病患者进行纵向KL-6监测可能改善个体化治疗。
研究设计与样本
- 研究纳入硬皮病肺研究II中比较霉酚酸酯与环磷酰胺治疗系统性硬化症相关间质性肺病的随机参与者,这些参与者有基线和12个月时的血液样本。
- 检测C反应蛋白、白细胞介素-6、C-X-C基序趋化因子配体4、CCL18和KL-6水平,并用逻辑回归模型评估这些生物标志物变化与24个月内进展性肺纤维化发生的关系。
- 142例随机参与者中,92例有纵向生物标志物测量和所需临床结局数据。
主要发现
- 92例参与者中,19例(21%)符合进展性肺纤维化标准。
- 在整个队列中,KL-6水平变化与进展性肺纤维化显著相关;发生进展性肺纤维化者KL-6升高,未发生者降低(平均变化±标准差 365.68±434.41 vs -207.45±670.26;P<0.001)。
- 在单用霉酚酸酯的参与者中,C反应蛋白和CXCL4水平变化也与进展性肺纤维化显著相关。
- 将KL-6变化加入基于该队列中与进展性肺纤维化相关的基线因素(性别、基线反流严重程度和CXCL4水平)的现有预测模型后,KL-6变化仍与进展性肺纤维化显著相关(比值比1.4;P=0.0002)。
关键数值与推荐
- 进展性肺纤维化定义为24个月内符合标准,92例中19例(21%)符合。
- KL-6变化与进展性肺纤维化的关联:发生进展性肺纤维化者平均变化±标准差 365.68±434.41,未发生者 -207.45±670.26(P<0.001)。
- 调整基线因素后,KL-6变化的比值比为1.4(P=0.0002)。
临床怎么用
- 原文未据此给出推荐;作者认为,对系统性硬化症相关间质性肺病患者测量纵向KL-6可能改善个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigated whether changes in circulating biomarkers predict progressive pulmonary fibrosis (PPF) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) receiving treatment. METHODS: Participants of the Scleroderma Lung Study II, which compared receiving mycophenolate mofetil (MMF) versus cyclophosphamide (CYC) for treating SSc-ILD, who had blood samples at baseline and 12 months were included. Levels for C-reactive protein (CRP), interleukin-6, C-X-C motif chemokine ligand (CXCL) 4, CCL18, and Krebs von den Lungen (KL)-6 were measured, and a logistic regression model evaluated relationships between changes in these biomarkers and the development of PPF by 24 months. RESULTS: A total of 92 of the 142 randomized participants had longitudinal biomarker measurements and the required clinical outcome data, with 19 participants (21%) meeting criteria for PPF. In the whole cohort, changes in KL-6 levels were significantly correlated with PPF. KL-6 increased in patients who developed PPF and decreased in patients who did not (mean change ± SD 365.68 ± 434.41 vs -207.45 ± 670.26; P < 0.001). In the arm of participants who received MMF alone, changes in CRP and CXCL4 levels were also significantly correlated with PPF. When added to an existing prediction model based on baseline factors associated with PPF in this cohort (sex, baseline reflux severity, and CXCL4 levels), the change in KL-6 remained significantly associated with PPF (odds ratio 1.4; P = 0.0002). CONCLUSION: Changes in the circulating levels of KL-6 after treatment with MMF or CYC predicted PPF, even after adjusting for baseline factors associated with PPF. Measuring longitudinal KL-6 in patients with SSc-ILD may improve how we personalize therapy in patients with SSc-ILD.
引用
- Volkmann ER, Wilhalme H, Tashkin DP, et al. Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Care Res (Hoboken). 2025. PMID: 39711034. doi:10.1002/acr.25485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。